ストックスクリーナーアプリを入手
1.38
4.55%
0.06
プレマーケット:
1.47
0.09
+6.52%
Celularity Inc (CELU) 最新ニュース
Celularity Director Philip Barach Updates Convertible Notes and Warrants, Acquires New Securities - Kalkine Media
Form 4 Celularity Inc For: 25 September - Investing.com India
A note’s share-conversion price fell from $1.66 to $1.50 as a Celularity (CELU) 10% owner bought more notes. - Stock Titan
1,177,000 warrants came with a Celularity (CELU) note purchase by a 10% owner's trust. - Stock Titan
Celularity Secures $10M Initial Financing in Planned $28M Recapitalization - citybiz
Celularity Inc. Announces Appointment of Philip A. Barach to Board - marketscreener.com
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements - Investing News Network
Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027 - Investing.com
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Drives 4.84% Share GainRevenue Breakdown Analysis - dars.gov.et
Celularity (NASDAQ: CELU) Achieves Nasdaq Compliance for Bid Price and Market Value - kalkinemedia.com
Form 8K Celularity Inc For: 14 September By Investing.com - Investing.com Nigeria
Celularity regains Nasdaq compliance for bid price and market value - Investing.com
Celularity regains Nasdaq compliance for bid price and market value By Investing.com - Investing.com Nigeria
Celularity Regains Nasdaq Compliance on Bid Price and Market Value Rules - Minichart
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Prevent 6.49% Stock DeclineDividend Growth Analysis - dars.gov.et
Celularity (CELU) Stock Slides 8% to $1.54 as Biotech Selling Pressure BuildsMA Cross Alert - siam.in
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Celularity Inc (CELUW) Peer Comparison – Compare with Others - Value Research
Celularity Inc (CELUW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Celularity (CELU) Stock News & Analysis - TechStock²
Celularity shares jump 138.5% after forecasting $300 million MuseCell manufacturing revenue - ts2.tech
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Singapore's MuseCell Innovations announces manufacturing collaboration with Celularity in US - BioSpectrum Asia
Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform - tradingview.com
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com India
Celularity (NASDAQ:CELU): Why Is It in Focus After It provided a fresh Nasdaq listing-compliance update? - Kalkine Media
Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance | CELU Stock News - Quiver Quantitative
Celularity Provides Update Regarding Nasdaq Listing Compliance - investingnews.com
Celularity (CELU) Latest Quarter: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Shares Move Lower 2.01% on the DayDividend Earnings Report - vinanet.vn
Celularity (CELU) Technicals: Declines 2.01% to $0.80 in the Current Update; Key Range: Support at $0.76 and Resistance at $0.84 Frame the Range on the DayAnalyst Upgrade Stocks - dars.gov.et
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move - siam.in
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - The Globe and Mail
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings: Narrower Loss Beats Estimates by 44.44% as Shares Rise 0.72Revenue Inflection Point - careplusvn.com
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistanceFast Moving Stocks - dars.gov.et
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - minichart.com.sg
Celularity removes chief commercial officer Rick Gonzalez effective immediately - Investing.com
Form 8K Celularity Inc For: 7 August By Investing.com - Investing.com Nigeria
Celularity terminates Rick Gonzalez as Chief Commercial Officer - TradingView
Celularity (NASDAQ: CELU) terminates employment of chief commercial officer - Stock Titan
Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026 - marketscreener.com
Celularity Inc (CELU) Stock News Today - TradingKey
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):